A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinsons Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinsons Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinsons Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinsons Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described.
